Method of treating atherogenic dyslipidemia
AssigneeNeurendo Pharma, LLC
InventorAnton H. Clemens
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.
Claims8
A method of treating atherogenic dyslipidemia, comprising administering to a subject a therapeutically effective amount of a selective kappa-receptor antagonist, or a pharmaceutically acceptable derivative thereof, wherein a μ-agonist is not co-administered and wherein the selective κ-receptor antagonist is characterized by its μ/κ antagonism Ke selectivity ratio, the ratio being greater than 35.
Dependencies are inferred from the claim text.